NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sensus Healthcare, Inc. ("Sensus" or the "Company") (NASDAQ:SRTS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Sensus and certain of its officers and/or […]

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Marex Group PLC ("Marex" or the "Company") (NASDAQ:MRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Marex and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NASDAQ:SPPI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE:SLQT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ:DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dyne and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. ("KBR" or the "Company") (NYSE:KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors

NEW YORK, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. ("BellRing" or the "Company") (NYSE:BRBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether BellRing and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Funko, Inc. ("Funko" or the "Company") (NASDAQ:FNKO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Funko and certain of its officers and/or directors

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation ("Encompass" or the "Company") (NYSE:EHC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Encompass and certain of its officers and/or

NEW YORK CITY, NY / ACCESS Newswire / August 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether GSK and certain of its officers and/or directors